KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer

Pancreatic cancer is a disease that has a very high fatality rate and one of the highest mortality ratios among all major cancers, remaining the fourth leading cause of cancer-related deaths in developed countries. The major treatment of pancreatic cancer is surgery; however, only 15-20% of patients...

Full description

Saved in:
Bibliographic Details
Published inCancers Vol. 9; no. 5; p. 42
Main Authors Cicenas, Jonas, Kvederaviciute, Kotryna, Meskinyte, Ingrida, Meskinyte-Kausiliene, Edita, Skeberdyte, Aiste
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 28.04.2017
MDPI
Subjects
BRCA1 protein
BRCA2 protein
Genomes
K-Ras protein
Mortality
Mutation
p53 Protein
Pancreatic cancer
Review
Smad4 protein
Surgery
Survival
Translocation
mutation
SMAD4
pancreatic cancer
CDKN2A
KRAS
BRCA1
genetic variant
BRCA2
TP53
Online AccessGet full text

Cover

More Information
Summary:Pancreatic cancer is a disease that has a very high fatality rate and one of the highest mortality ratios among all major cancers, remaining the fourth leading cause of cancer-related deaths in developed countries. The major treatment of pancreatic cancer is surgery; however, only 15-20% of patients are candidates for it at the diagnosis of disease. On the other hand, survival in patients, who undergo surgery, is less than 30%. In most cancers, genome stability is disturbed and pancreatic cancer is not the exception. Approximately 97% of pancreatic cancers have gene derangements, defined by point mutations, amplifications, deletions, translocations, and inversions. This review describes the most frequent genetic alterations found in pancreatic cancer.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers9050042